Sinopharm Group (000028.SZ) reported a net profit attributable to shareholders of RMB 952 million for the first three quarters, down 0.48% year on year.

Zhitong Finance APP News, Sinopharm (000028.SZ) released its 2026 Q1-Q3 performance express report. From January to September 2026, the company achieved operating revenue of RMB 55.066 billion, a year-on-year decrease of 0.11%; net profit attributable to shareholders of the listed company was RMB 952 million, a year-on-year decrease of 0.48%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was RMB 945 million, a year-on-year increase of 2.36%.